Evidence map›Paper›PMID 32425339›Full record

ArticleJournal of toxicologic pathology2020

Tissue-specific effects of an anti-desmoglein-3 ADCC antibody due to expression of the target antigen and physiological characteristics of the mouse vagina.

Etsuko Fujii, Shinichi Funahashi, Kenji Taniguchi, Shigeto Kawai, Kiyotaka Nakano, Atsuhiko Kato, Masami Suzuki

Open access · diamondAbstract read
In one paragraph

Article in Journal of toxicologic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Etsuko FujiiForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 6-1 Komaba 4, Meguro, Tokyo 153-8904, Japan.
Shinichi FunahashiForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 6-1 Komaba 4, Meguro, Tokyo 153-8904, Japan.
Kenji TaniguchiChugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Shigeto KawaiForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 6-1 Komaba 4, Meguro, Tokyo 153-8904, Japan.
Kiyotaka NakanoForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 6-1 Komaba 4, Meguro, Tokyo 153-8904, Japan.
Atsuhiko KatoChugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Masami SuzukiForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 6-1 Komaba 4, Meguro, Tokyo 153-8904, Japan.
Tokyo Metropolitan Komaba High School · JPChugai Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmoglein-3 (DSG3) is a potential target of cytotoxic antibody therapy for squamous cell carcinomas but is also expressed in various normal squamous epithelia. We obtained information about DSG3 distribution in mouse tissues by immunohistochemistry and conducted an intravenous multiple-dose study in mouse to estimate the toxic potential of anti-DSG3 therapy. DSG3 was expressed in the squamous epithelium of several organs including the skin, esophagus, tongue, forestomach, eye, and vagina. It was expressed at all estrous cycles of the vagina with changes in distribution patterns along with the structural changes in each cycle, and expression was reduced in ovariectomized (OVX) mice. On the administration of the antibody, there was disarrangement of the vaginal mucosal epithelium with formation of miroabscess, increased granulocyte infiltration, and single cell necrosis. Despite similar expression levels of DSG3 in other tissues, histopathological changes were limited to the vagina. The severity of the changes was reduced by ovariectomy. From these findings, the lesions were thought to be related to the drastic change in the histological structure of the vaginal mucosa accompanying the estrous cycle. Thus, we have shown that the changing expression of target antigen distribution and its relationship with physiological changes in tissue structure are important features for estimating the toxic potential of cytotoxic antibody therapy.

Indexed as

cytotoxic antibodydesmoglein-3estrous cycletissue distributionvagina

Identifiers

PMID32425339
PMCPMC7218237
OpenAlexW2996037630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.